These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 21420365)

  • 1. Neuroprotective agents: cannabinoids.
    Sánchez AJ; García-Merino A
    Clin Immunol; 2012 Jan; 142(1):57-67. PubMed ID: 21420365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cannabinoid system and neuroinflammation: implications for multiple sclerosis.
    Correa F; Docagne F; Mestre L; Loría F; Hernangómez M; Borrell J; Guaza C
    Neuroimmunomodulation; 2007; 14(3-4):182-7. PubMed ID: 18073512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of CB2 receptors in neuroprotective effects of cannabinoids.
    Fernández-Ruiz J; Pazos MR; García-Arencibia M; Sagredo O; Ramos JA
    Mol Cell Endocrinol; 2008 Apr; 286(1-2 Suppl 1):S91-6. PubMed ID: 18291574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glatiramer acetate for the treatment of multiple sclerosis: evidence for a dual anti-inflammatory and neuroprotective role.
    Liblau R
    J Neurol Sci; 2009 Dec; 287 Suppl 1():S17-23. PubMed ID: 20106343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experimental autoimmune encephalomyelitis disrupts endocannabinoid-mediated neuroprotection.
    Witting A; Chen L; Cudaback E; Straiker A; Walter L; Rickman B; Möller T; Brosnan C; Stella N
    Proc Natl Acad Sci U S A; 2006 Apr; 103(16):6362-7. PubMed ID: 16571660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The role of endocannabinoid system in physiological and pathological processes in the eye].
    Nadolska K; Goś R
    Klin Oczna; 2008; 110(10-12):392-6. PubMed ID: 19195174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cannabinoid-mediated neuroprotection, not immunosuppression, may be more relevant to multiple sclerosis.
    Croxford JL; Pryce G; Jackson SJ; Ledent C; Giovannoni G; Pertwee RG; Yamamura T; Baker D
    J Neuroimmunol; 2008 Jan; 193(1-2):120-9. PubMed ID: 18037503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cannabinoid system and neuroinflammation:therapeutic perspectives in multiple sclerosis].
    Mestre L; Correa F; Docagne F; Clemente D; Ortega-Gutiérrez S; Arévalo-Martín A; Molina-Holgado E; Borrell J; Guaza C
    Rev Neurol; 2006 Nov 1-15; 43(9):541-8. PubMed ID: 17072810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Linkage between immunomodulation, neuroprotection and neurogenesis.
    Aharoni R; Arnon R
    Drug News Perspect; 2009; 22(6):301-12. PubMed ID: 19771319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cannabinoids and experimental models of multiple sclerosis.
    Kubajewska I; Constantinescu CS
    Immunobiology; 2010 Aug; 215(8):647-57. PubMed ID: 19765854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cannabinoids and the immune system: an overview.
    Tanasescu R; Constantinescu CS
    Immunobiology; 2010 Aug; 215(8):588-97. PubMed ID: 20153077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Excitotoxicity in a chronic model of multiple sclerosis: Neuroprotective effects of cannabinoids through CB1 and CB2 receptor activation.
    Docagne F; Muñetón V; Clemente D; Ali C; Loría F; Correa F; Hernangómez M; Mestre L; Vivien D; Guaza C
    Mol Cell Neurosci; 2007 Apr; 34(4):551-61. PubMed ID: 17229577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The G protein-coupled receptor 55 ligand l-α-lysophosphatidylinositol exerts microglia-dependent neuroprotection after excitotoxic lesion.
    Kallendrusch S; Kremzow S; Nowicki M; Grabiec U; Winkelmann R; Benz A; Kraft R; Bechmann I; Dehghani F; Koch M
    Glia; 2013 Nov; 61(11):1822-31. PubMed ID: 24038453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An endocannabinoid tone limits excitotoxicity in vitro and in a model of multiple sclerosis.
    Loría F; Petrosino S; Hernangómez M; Mestre L; Spagnolo A; Correa F; Di Marzo V; Docagne F; Guaza C
    Neurobiol Dis; 2010 Jan; 37(1):166-76. PubMed ID: 19815071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pharmacology of cannabinoid receptors and their ligands: an overview.
    Pertwee RG
    Int J Obes (Lond); 2006 Apr; 30 Suppl 1():S13-8. PubMed ID: 16570099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of neurotrophic factors in the pathology and treatment of multiple sclerosis.
    Mirowska-Guzel D
    Immunopharmacol Immunotoxicol; 2009; 31(1):32-8. PubMed ID: 18792835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucocorticoids in multiple sclerosis and experimental autoimmune encephalomyelitis.
    Reichardt HM; Gold R; Lühder F
    Expert Rev Neurother; 2006 Nov; 6(11):1657-70. PubMed ID: 17144780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transmembrane tumour necrosis factor is neuroprotective and regulates experimental autoimmune encephalomyelitis via neuronal nuclear factor-kappaB.
    Taoufik E; Tseveleki V; Chu SY; Tselios T; Karin M; Lassmann H; Szymkowski DE; Probert L
    Brain; 2011 Sep; 134(Pt 9):2722-35. PubMed ID: 21908876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease.
    Lastres-Becker I; Molina-Holgado F; Ramos JA; Mechoulam R; Fernández-Ruiz J
    Neurobiol Dis; 2005; 19(1-2):96-107. PubMed ID: 15837565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brain-derived neurotrophic factor and TrkB receptor in experimental autoimmune encephalomyelitis and multiple sclerosis.
    De Santi L; Annunziata P; Sessa E; Bramanti P
    J Neurol Sci; 2009 Dec; 287(1-2):17-26. PubMed ID: 19758606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.